# EDGAR Filing Document

**Accession Number:** 0000882095
**File Stem:** 0001123292-25-000309
**Filing Date:** 2025-7
**Character Count:** 9802
**Document Hash:** 045eefb06b3d6e89a0d8d110fa31154d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001123292-25-000309.hdr.sgml**: 20250715

**ACCESSION NUMBER**: 0001123292-25-000309

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250715

**DATE AS OF CHANGE**: 20250715

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Arcus Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001724521
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473898435
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90423
- **FILM NUMBER:** 251125981

**BUSINESS ADDRESS:**
- **STREET 1:** 3928 POINT EDEN WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545
- **BUSINESS PHONE:** (510) 694-6200

**MAIL ADDRESS:**
- **STREET 1:** 3928 POINT EDEN WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 5)**

**Arcus Biosciences, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001**

*(Title of Class of Securities)*

**03969F109**

*(CUSIP Number)*

**Gilead Sciences, Inc.**<br>333 Lakeside Drive<br>Foster City CA 94404<br>650-574-3000

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**07/13/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **03969F109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**GILEAD SCIENCES, INC.** | Name of reporting person<br>**GILEAD SCIENCES, INC.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**31424760.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**31424760.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**31424760.00** | Aggregate amount beneficially owned by each reporting person<br>**31424760.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**29.7%** | Percent of class represented by amount in Row (11)<br>**29.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** The number of shares reported in rows 7, 9, and 11 consists of (i) 2,200,000 shares of the common stock, par value $0.0001 per share (the "Common Stock"), of Arcus Biosciences, Inc. (the "Issuer") purchased in the 2020 Public Offering, (ii) the initial purchase of 5,963,029 shares of Common Stock pursuant to the Purchase Agreement, (iii) the subsequent purchase of 5,650,000 shares of Common Stock pursuant to the Amended and Restated Purchase Agreement, (iv) the subsequent purchase of 1,010,000 shares of Common Stock pursuant to the Second Amended and Restated Purchase Agreement, (v) the subsequent purchase of 15,238,095 shares of Common Stock of the Issuer pursuant to the Third Amended and Restated Purchase Agreement, and (vi) the subsequent purchase of 1,363,636 shares of Common Stock pursuant to the Public Offering.

The percent reported in row 13 is calculated based upon 105,885,138 shares of Common Stock issued and outstanding as of May 1, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on May 6, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001

**(b) Name of Issuer:**
Arcus Biosciences, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
3928 Point Eden Way, Hayward, CA, 94545

This Amendment No. 5 (the "Amendment") amends the initial Schedule 13D filed by the Reporting Person on July 17, 2020, as amended by Amendment No. 1 to Schedule 13D filed with the SEC by the Reporting Person on February 2, 2021, Amendment No. 2 to Schedule 13D filed with the SEC by the Reporting Person on July 6, 2023, Amendment No. 3 to Schedule 13D filed with the SEC by the Reporting Person on January 31, 2024, and Amendment No. 4 to Schedule 13D filed with the SEC by the Reporting Person on March 5, 2025 (the "Original Schedule 13D," and as amended by Amendment No. 5, the "Schedule 13D"). Capitalized terms used but not defined in this Amendment shall have the same meanings ascribed to them in the Original Schedule 13D.

**Item 4. Purpose of Transaction**

Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following:

On July 13, 2025, the Reporting Person's option to purchase additional shares from the Issuer, up to a maximum of 35% of the Issuer's then-outstanding Common Stock, expired.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Schedule 13D is hereby amended and restated to read as follows:

Number of shares of Common Stock beneficially owned:

	Gilead - 31,424,760 shares

	Jeffrey A. Bluestone - 7,156 shares

	Percent of class:

	Gilead - 29.7%

	Jeffrey A. Bluestone - 0.01%

	The number of shares of Common Stock beneficially owned by Gilead consists of (i) 2,200,000 shares of Common Stock purchased in the 2020 Public Offering, (ii) the initial purchase of 5,963,029 shares of Common Stock pursuant to the Purchase Agreement, (iii) the subsequent purchase of 5,650,000 shares of Common Stock pursuant to the Amended and Restated Purchase Agreement, (iv) the subsequent purchase of 1,010,000 shares of Common Stock pursuant to the Second Amended and Restated Purchase Agreement, (v) the subsequent purchase of 15,238,095 shares of Common Stock pursuant to the Third Amended and Restated Purchase Agreement, and (vi) the subsequent purchase of 1,363,636 shares of Common Stock pursuant to the Public Offering. The number of shares of Common Stock beneficially owned by Mr. Bluestone consists of options to purchase 7,156 shares of Common Stock exercisable within 60 days.

	The percentage ownership for Gilead was calculated based upon 105,885,138 shares of common stock of the Issuer issued and outstanding as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. The percentage ownership for Mr. Bluestone was calculated based upon 105,892,294 shares of Common Stock issued and outstanding, based on 105,885,138 shares of Common Stock issued and outstanding and assuming the immediate exercise in full by Mr. Bluestone of his options.

	To the best knowledge of the Reporting Person, none of the individuals listed on Schedule I beneficially owns any of the Issuer's Common Stock, except Mr. Bluestone, who has received options to purchase shares of Common Stock in partial payment for his service on the Issuer's Scientific Advisory Board.

**(b)**
Item 5(b) of the Schedule 13D is hereby amended and restated to read as follows:

Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote:

	Gilead - 31,424,760 shares

	Jeffrey A. Bluestone - 7,156 shares

(ii) Shared power to vote or to direct the vote:

	Gilead - 0 shares

	Jeffrey A. Bluestone - 0 shares

(iii) Sole power to dispose or to direct the disposition of:

	Gilead - 31,424,760 shares

	Jeffrey A. Bluestone - 7,156 shares

(iv) Shared power to dispose or to direct the disposition of:

	Gilead - 0 shares

	Jeffrey A. Bluestone - 0 shares

**(c)**
—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** GILEAD SCIENCES, INC.

**Signature:** /s/ Andrew D. Dickinson

**Name/Title:** Andrew D. Dickinson, Executive Vice President and Chief Financial Officer

**Date:** 07/15/2025